Market Cap | 77.93M | P/E | - | EPS this Y | 47.10% | Ern Qtrly Grth | - |
Income | -76.4M | Forward P/E | -1.15 | EPS next Y | 34.70% | 50D Avg Chg | 1.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | - |
Dividend | N/A | Price/Book | 0.92 | EPS next 5Y | - | 52W High Chg | -42.00% |
Recommedations | 2.00 | Quick Ratio | 2.80 | Shares Outstanding | 36.91M | 52W Low Chg | 46.00% |
Insider Own | 31.90% | ROA | -49.44% | Shares Float | 16.43M | Beta | -0.08 |
Inst Own | 49.46% | ROE | -107.25% | Shares Shorted/Prior | 379.49K/57.63K | Price | 2.84 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 15,374 | Target Price | 5.50 |
Oper. Margin | - | Earnings Date | Apr 1 | Volume | 831 | Change | 1.07% |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Chardan Capital | Buy | May 30, 23 |
Chardan Capital | Buy | May 11, 23 |
Morgan Stanley | Overweight | Jan 27, 23 |
Chardan Capital | Buy | Dec 21, 22 |
Raymond James | Outperform | Nov 10, 22 |
Morgan Stanley | Overweight | Aug 10, 22 |
HC Wainwright & Co. | Buy | Jan 10, 22 |
Raymond James | Outperform | Nov 16, 21 |
Cowen & Co. | Outperform | Nov 16, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Atlas Venture Fund XI, L.P. | 10% Owner 10% Owner | Jan 11 | Sell | 0.85 | 4,235 | 3,600 | 734,813 | 01/16/24 |
Bain Capital Life Sciences Inv... | 10% Owner 10% Owner | Dec 08 | Buy | 9.82 | 42,469 | 417,046 | 2,805,413 | 12/10/21 |
Flynn James E | - - | Oct 26 | Buy | 16 | 775,000 | 12,400,000 | 1,143,972 | 10/28/21 |